2024
The single-cell opioid responses in the context of HIV (SCORCH) consortium
Ament S, Campbell R, Lobo M, Receveur J, Agrawal K, Borjabad A, Byrareddy S, Chang L, Clarke D, Emani P, Gabuzda D, Gaulton K, Giglio M, Giorgi F, Gok B, Guda C, Hadas E, Herb B, Hu W, Huttner A, Ishmam M, Jacobs M, Kelschenbach J, Kim D, Lee C, Liu S, Liu X, Madras B, Mahurkar A, Mash D, Mukamel E, Niu M, O’Connor R, Pagan C, Pang A, Pillai P, Repunte-Canonigo V, Ruzicka W, Stanley J, Tickle T, Tsai S, Wang A, Wills L, Wilson A, Wright S, Xu S, Yang J, Zand M, Zhang L, Zhang J, Akbarian S, Buch S, Cheng C, Corley M, Fox H, Gerstein M, Gummuluru S, Heiman M, Ho Y, Kellis M, Kenny P, Kluger Y, Milner T, Moore D, Morgello S, Ndhlovu L, Rana T, Sanna P, Satterlee J, Sestan N, Spector S, Spudich S, Tilgner H, Volsky D, White O, Williams D, Zeng H. The single-cell opioid responses in the context of HIV (SCORCH) consortium. Molecular Psychiatry 2024, 29: 3950-3961. PMID: 38879719, PMCID: PMC11609103, DOI: 10.1038/s41380-024-02620-7.Peer-Reviewed Original ResearchContext of human immunodeficiency virusHuman immunodeficiency virusSubstance use disordersOpioid responseAnimal modelsEffects of substance use disordersOpioid pain medicationsPrevalence of co-morbid conditionsChronic pain syndromesStage of diseaseCell typesAffected cell typesCo-morbid conditionsPain syndromeImmunodeficiency virusPain medicationOpioid addictionIncreased riskRisk factorsHuman cohortsDrug addictionBrain tissue collectionBrain cell typesTissue collectionSingle-cell levelEx situ liver resection for intrahepatic cholangiocarcinoma: survival analysis and comparison to systemic chemotherapy
Nieddu E, Billato I, Peluso C, Furlanetto A, Lazzari S, D'Amico F, Cillo U, Gringeri E. Ex situ liver resection for intrahepatic cholangiocarcinoma: survival analysis and comparison to systemic chemotherapy. Digestive And Liver Disease 2024, 56: s42. DOI: 10.1016/j.dld.2024.01.067.Peer-Reviewed Original ResearchProgression-free survivalCA19-9 levelsEx situ liver resectionOverall survivalIntrahepatic cholangiocarcinomaEx situ surgeryStage of diseasePerformance statusSystemic chemotherapySurgical resectionLiver resectionLiver functionHigh-volume hepatobiliary centersLower stage of diseaseMedian progression-free survivalTreated with surgical resectionEvaluate long-term outcomesSurvival analysisEx situ resectionNon-parametric log-rank testTreated with chemotherapyLog-rank testLiver function testsCox regression analysisLong-term outcomes
2023
Trends in Receipt of Adjuvant Chemotherapy and its Impact on Survival in Resected Biliary Tract Cancers
Rhodin K, Liu A, Bartholomew A, Kramer R, Parameswaran A, Uronis H, Strickler J, Hsu D, Morse M, Shah K, Herbert G, Zani S, Nussbaum D, Allen P, Lidsky M. Trends in Receipt of Adjuvant Chemotherapy and its Impact on Survival in Resected Biliary Tract Cancers. Annals Of Surgical Oncology 2023, 30: 4813-4821. PMID: 37188803, PMCID: PMC10330866, DOI: 10.1245/s10434-023-13567-4.Peer-Reviewed Original ResearchConceptsBiliary tract cancerResected biliary tract cancerNational Cancer DatabaseAdjuvant chemotherapyGallbladder cancerIntrahepatic CCAExtrahepatic CCAMethodsThe National Cancer DatabaseMultivariate Cox proportional hazards methodBiliary tract cancer subtypesOdds of ACCox proportional hazards methodReceipt of adjuvant chemotherapyCurative-intent treatmentReceipt of ACFactors associated with receiptYear of diagnosisHigher comorbidity scoreProportional hazards methodStage of diseaseFactors associated with ACMultivariate logistic regressionAssociated with reduced oddsIII diseasePositive marginsBreast Cancer Mode of Detection in a Population-Based Cohort
Basappa S, Finney Rutten L, Hruska C, Olson J, Jacobson D, Rhodes D. Breast Cancer Mode of Detection in a Population-Based Cohort. Mayo Clinic Proceedings 2023, 98: 278-289. PMID: 36737116, PMCID: PMC9907001, DOI: 10.1016/j.mayocp.2022.10.010.Peer-Reviewed Original ResearchConceptsPopulation-based cohortBreast cancerAdvanced cancerBreast densityRetrospective medical record reviewDense breastsPositive lymph nodesFirst-time diagnosisRochester Epidemiology ProjectMedical record reviewStage of diseaseLarger tumor sizeWomen age 40High-grade tumorsMultiple logistic regressionYears of ageLymph nodesRecord reviewTumor characteristicsTumor sizeCancer characteristicsCancer modeAge 40Clinical attentionCancer
2022
Survival in male breast cancer over the past 3 decades
Leone J, Freedman R, Leone J, Tolaney S, Vallejo C, Leone B, Winer E, Lin N, Hassett M. Survival in male breast cancer over the past 3 decades. Journal Of The National Cancer Institute 2022, 115: 421-428. PMID: 36583555, PMCID: PMC10086618, DOI: 10.1093/jnci/djac241.Peer-Reviewed Original ResearchConceptsBreast cancer-specific survivalMale breast cancerOverall survivalBreast cancerMultivariable Cox regressionCancer-specific survivalEnd Results registryYear of diagnosisBreast cancer mortalityStage of diseaseLog-rank testCox regressionCancer mortalityKaplan-MeierIndependent associationCox modelSignificant improvementSignificant associationCancerLife expectancyDiagnosisSurvivalSignificant differencesPatientsMen
2020
Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19
Zaorsky NG, Yu JB, McBride SM, Dess RT, Jackson WC, Mahal BA, Chen R, Choudhury A, Henry A, Syndikus I, Mitin T, Tree A, Kishan AU, Spratt DE. Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Advances In Radiation Oncology 2020, 5: 26-32. PMID: 33145460, PMCID: PMC7598436, DOI: 10.1016/j.adro.2020.10.003.Peer-Reviewed Original ResearchProstate cancerM1 diseaseNational Comprehensive Cancer Network risk groupClinical node-positive diseaseFavorable intermediate-risk diseaseRadiation therapy recommendationsIntermediate-risk diseaseNeoadjuvant hormone therapyNode-positive diseaseStage of diseaseTreatment of patientsProstate cancer stageRadiation oncology departmentsGlobal pandemicAdjuvant radiationModerate hypofractionationHormone therapyPositive diseaseRoutine visitsCancer stageTherapy recommendationsOncology departmentRisk groupsRadiation therapyTelemedicine consultationsProstate Cancer Radiation Therapy Recommendations in Response to COVID-19
Zaorsky NG, Yu JB, McBride SM, Dess RT, Jackson WC, Mahal BA, Chen R, Choudhury A, Henry A, Syndikus I, Mitin T, Tree A, Kishan AU, Spratt DE. Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Advances In Radiation Oncology 2020, 5: 659-665. PMID: 32292839, PMCID: PMC7118610, DOI: 10.1016/j.adro.2020.03.010.Peer-Reviewed Original ResearchProstate cancerM1 diseaseNational Comprehensive Cancer Network risk groupClinical node-positive diseaseFavorable intermediate-risk diseaseRadiation therapy recommendationsIntermediate-risk diseaseNeoadjuvant hormone therapyNode-positive diseaseStage of diseaseTreatment of patientsProstate cancer stageRadiation oncology departmentsGlobal pandemicAdjuvant radiationModerate hypofractionationHormone therapyPositive diseaseRoutine visitsCancer stageTherapy recommendationsOncology departmentRisk groupsRadiation therapyTelemedicine consultations
2019
Dose-Dependent Decreased Fertility in Response to the Burden of Endometriosis in a Murine Model
Rosa-e-Silva ACJS, Rosa-e-Silva JC, Mamillapalli R, Taylor HS. Dose-Dependent Decreased Fertility in Response to the Burden of Endometriosis in a Murine Model. Reproductive Sciences 2019, 26: 1395-1400. PMID: 31274059, PMCID: PMC6949971, DOI: 10.1177/1933719119859438.Peer-Reviewed Original ResearchConceptsMurine modelCurrent clinical staging systemBurden of endometriosisClinical staging systemClear dose-response relationshipDegree of painStage of diseaseEffect of endometriosisMechanism of infertilityGroups of miceSequelae of diseaseSeverity of symptomsDose-response relationshipSham surgery controlsActive diseaseDisease activityPelvic painStaging systemEarly recognitionEctopic tissueEndometrial cellsGynecological diseasesSurgery controlsPregnancy rateUterine tissuePrevalence of False-Negative Results of Intraoperative Consultation on Surgical Margins During Resection of Gastric and Gastroesophageal Adenocarcinoma
McAuliffe JC, Tang LH, Kamrani K, Olino K, Klimstra DS, Brennan MF, Coit DG. Prevalence of False-Negative Results of Intraoperative Consultation on Surgical Margins During Resection of Gastric and Gastroesophageal Adenocarcinoma. JAMA Surgery 2019, 154: 126-132. PMID: 30422226, PMCID: PMC6439656, DOI: 10.1001/jamasurg.2018.3863.Peer-Reviewed Original ResearchConceptsCurative-intent resectionSurgical marginsIOC resultsGastroesophageal adenocarcinomaNeoadjuvant radiotherapyIntraoperative consultationFN resultsClinical implicationsDuodenal marginsFalse-negative resultsSingle institution referral centerResection of gastricDisease-specific survivalStage of diseaseTrue-positive resultsGastric marginSurgical fitnessCurative intentReferral centerSubsequent resectionEsophageal resectionRetrospective studyGastrointestinal pathologistsDiffuse diseaseTumor location
2018
Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors
Pulvirenti A, Rao D, Mcintyre C, Gonen M, Tang L, Klimstra D, Fleisher M, Ramanathan L, Reidy-Lagunes D, Allen P. Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors. Hepato Pancreato Biliary 2018, 21: 612-618. PMID: 30366884, PMCID: PMC8720376, DOI: 10.1016/j.hpb.2018.09.016.Peer-Reviewed Original ResearchConceptsPancreatic neuroendocrine tumorsNeuroendocrine tumorsPancreatic neoplasmsCgA levelsAssociated with disease-specific survivalChromogranin ASerum chromogranin ADisease-specific survivalElevated CgA levelsKaplan-Meier methodStage of diseaseCgA measurementElevated CgATumor gradePrognostic significanceCgA valuesPrognostic valuePrognostic markerPanNETsHealthy controlsPathological factorsDiagnostic valueClinical biomarkersInclusion criteriaPatientsBreast cancer‐specific survival by age: Worse outcomes for the oldest patients
Freedman RA, Keating NL, Lin NU, Winer EP, Vaz‐Luis I, Lii J, Exman P, Barry WT. Breast cancer‐specific survival by age: Worse outcomes for the oldest patients. Cancer 2018, 124: 2184-2191. PMID: 29499074, PMCID: PMC5935594, DOI: 10.1002/cncr.31308.Peer-Reviewed Original ResearchConceptsBreast cancer-specific deathCancer-specific deathTriple-negative diseaseHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Growth factor receptor 2Breast cancer outcomesOlder patientsFactor receptor 2Breast cancerCancer outcomesReceptor 2Disease subtypesWorse breast cancer outcomesHR-positive diseaseCancer stage IEnd Results (SEER) dataAmerican Joint CommitteePopulation-based cohortStage of diseaseGray regression modelsAdjusted hazardClinical variablesDisease stageHigh risk
2017
Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance
Mahal A, Mahal B, Nguyen P, Yu J. Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance. Cancer 2017, 124: 752-759. PMID: 29084350, DOI: 10.1002/cncr.31106.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityMetastatic diseaseCancer-specific mortalityProstate cancer outcomesOutcomes of patientsMedicaid insuranceEnd Results ProgramReceipt of therapyStage of diseaseAfrican American patientsInsurance statusPrivately insured cohortDefinitive treatmentProstate cancerLocalized CaPResults ProgramPrivate insuranceCAP outcomesCancer outcomesAmerican patientsPatientsProstateRacial disparitiesAssociated with raceAssociated with racial disparitiesHistory of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium
Minlikeeva AN, Consortium JL, Freudenheim KH, Eng RA, Cannioto G, Friel JB, Szender B, Segal K, Odunsi P, Mayor B, Diergaarde E, Zsiros LE, Kelemen M, Köbel H, Steed A, deFazio SJ, Group PA, Jordan MW, Fasching HA, Beckmann MA, Risch JA, Rossing J, Doherty MT, Chang-Claude T, Goodman R, Dörk F, Edwards RB, Modugno K, Ness M, Matsuo BY, Mizuno EL, Karlan SK, Goode E, Kjær JM, Høgdall KL, Schildkraut DW, Terry EV, Cramer LE, Bandera LA, Paddock LFAG, Kiemeney R, Massuger H, Sutphen A, Anton-Culver U, Ziogas SA, Menon SJ, Gayther A, Ramus CL, Gentry-Maharaj AH, Pearce J, Wu A, Kupryjanczyk PM, Jensen KB, Webb P, Moysich K. History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers & Prevention 2017, 26: 1470-1473. PMID: 28864456, PMCID: PMC5649363, DOI: 10.1158/1055-9965.epi-17-0367.Peer-Reviewed Original ResearchConceptsProgression-free survivalHistory of endometriosisStage of diseaseOvarian cancer patientsOvarian cancer outcomeCancer outcomesCancer patientsCox proportional hazards regression modelProportional hazards regression modelsHazards regression modelsInvasive ovarian carcinomasOvarian cancer prognosisOvarian Cancer Association ConsortiumPooled HRsConcurrent comorbiditiesHistologic subtypeOvarian carcinomaChronic diseasesOvarian cancerWeight statusNeurologic diseaseCancer prognosisComorbiditiesTreatment efficacyNeurological diseasesPositive aspects of having had cancer: A mixed‐methods analysis of responses from the American Cancer Society Study of Cancer Survivors‐II (SCS‐II)
Adorno G, Lopez E, Burg MA, Loerzel V, Killian M, Dailey AB, Iennaco JD, Wallace C, Sharma DKB, Stein K. Positive aspects of having had cancer: A mixed‐methods analysis of responses from the American Cancer Society Study of Cancer Survivors‐II (SCS‐II). Psycho-Oncology 2017, 27: 1412-1425. PMID: 28637082, DOI: 10.1002/pon.4484.Peer-Reviewed Original ResearchConceptsAmerican Cancer Society's StudyStage of diseaseCancer survivorsSurvivor cohortPostcancer diagnosisLength of survivorshipCancer Survivors-IICancer survivors' perceptionsHealth-related changesClinical variablesLife measuresCancer ScaleCancerCancer typesSurvivorsDiagnosisCancer diagnosisBenefit findingSociodemographicsMedical supportCohortSociety studiesSurvivors' perceptionsDiseaseNational sampleThe skin as a window to the blood: Cutaneous manifestations of myeloid malignancies
Li AW, Yin ES, Stahl M, Kim TK, Panse G, Zeidan AM, Leventhal JS. The skin as a window to the blood: Cutaneous manifestations of myeloid malignancies. Blood Reviews 2017, 31: 370-388. PMID: 28732587, DOI: 10.1016/j.blre.2017.07.003.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCutaneous manifestationsMyeloid malignanciesMyeloid diseasesCommon cutaneous manifestationStage of diseaseHematologists/oncologistsSignificant clinical implicationsMalignant hematopoietic cellsCutaneous involvementSkin manifestationsTargeted agentsSkin findingsClinical reviewCutaneous reactionsDermatologic findingsPrognostic valueImmune statusDiagnostic challengeEarly recognitionHematologic malignanciesMalignancyClinical implicationsDiseaseManifestationsHematopoietic cells
2016
High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome
Delgado E, Boisen M, Laskey R, Chen R, Song C, Sallit J, Yochum Z, Andersen C, Sikora M, Wagner J, Safe S, Elishaev E, Lee A, Edwards R, Haluska P, Tseng G, Schurdak M, Oesterreich S. High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome. Gynecologic Oncology 2016, 141: 348-356. PMID: 26946093, PMCID: PMC5154956, DOI: 10.1016/j.ygyno.2016.02.030.Peer-Reviewed Original ResearchConceptsHigh-grade serous ovarian cancerWorse progression-free survivalProgression-free survivalOvarian cancer cell linesCancer cell linesFree survivalNuclear receptorsOvarian cancerOvarian cancer tissue samplesCell linesGrade serous ovarian cancerExpression of NR4A1Ovarian cancer pathogenesisStage of diseaseTCGA dataNormal ovarian tissuesSerous ovarian cancerCancer tissue samplesNormal ovarian samplesRelevant nuclear receptorsHGSOC cell linesCritical nuclear receptorOverexpression of NR4A1Orphan nuclear receptor NR4A1Ovarian tumorsKnowledge of Cancer Stage among Women with Nonmetastatic Breast Cancer
Hinchey J, Goldberg J, Linsky S, Linsky R, Jeon S, Schulman-Green D. Knowledge of Cancer Stage among Women with Nonmetastatic Breast Cancer. Journal Of Palliative Medicine 2016, 19: 314-317. PMID: 26855201, PMCID: PMC8109048, DOI: 10.1089/jpm.2015.0133.Peer-Reviewed Original ResearchConceptsChronic Disease Self-Efficacy ScaleElectronic medical recordsMedical Communication Competence ScaleControl Preferences ScaleCancer stageBreast cancerCare optionsStage I breast cancerI breast cancerNonmetastatic breast cancerStage of diseaseSelf-management interventionsStage of cancerEarly cancer stagesNonmetastatic diseaseClinical variablesMean ageHospital AnxietyMedical recordsIllness ScaleDepression ScalePatient understandingPatient's abilityStage IIIYounger age
2015
Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL
Sethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL. Blood 2015, 126: 1441. DOI: 10.1182/blood.v126.23.1441.1441.Peer-Reviewed Original ResearchNodular sclerosis Hodgkin lymphomaProgression-free survivalOutcomes of patientsAdvanced stage diseaseOverall survivalComplete responseHodgkin's lymphomaB symptomsStage diseaseSV groupAchievement of CRInferior progression-free survivalMedian progression-free survivalHodgkin/Reed-Sternberg cellsInstitutional IRB approvalMedian overall survivalStandard ABVD chemotherapyStandard salvage regimensHigh-dose therapyKaplan-Meier methodOnly independent predictorStem cell transplantStage of diseaseCompletion of treatmentNew immunomodulatory agentsThe Evolving Landscape of HER2 Targeting in Breast Cancer
Moasser MM, Krop IE. The Evolving Landscape of HER2 Targeting in Breast Cancer. JAMA Oncology 2015, 1: 1154. PMID: 26204261, DOI: 10.1001/jamaoncol.2015.2286.Peer-Reviewed Original ResearchConceptsTreatment of HER2Breast cancerImmunologic effectorsHER2 targetingSubstantial single-agent activityHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Value of HER2Lines of therapyGrowth factor receptor 2Single-agent activityLate-stage diseaseStage of diseaseUseful predictive biomarkerHER2 inhibitor lapatinibFactor receptor 2Variety of cytotoxicModest efficacyTrastuzumab resistancePredictive biomarkersCell surface expressionImmunologic activityInhibitor lapatinibReceptor 2Advanced stage
2014
Relationships among patients’ ability to identify their cancer stage, knowledge of care options, and management of transitions.
Hinchey J, Goldberg J, Linsky S, Linsky R, Jeon S, Schulman-Green D. Relationships among patients’ ability to identify their cancer stage, knowledge of care options, and management of transitions. Journal Of Clinical Oncology 2014, 32: 224-224. DOI: 10.1200/jco.2014.32.31_suppl.224.Peer-Reviewed Original ResearchElectronic medical recordsCancer stageBreast cancerCare optionsStage IV breast cancerNon-metastatic breast cancerStage I breast cancerI breast cancerStage of diseaseStage of cancerEarly cancer stagesSelf-management studiesSample of womenNonmetastatic diseaseClinical variablesMean ageMedical recordsStage IIIYounger ageStage IICancerLogistic regressionPatientsWomenDisease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply